HER2 immunohistochemistry staining positivity is strongly predictive of tumor response to neoadjuvant chemotherapy in HER2 positive breast cancer.

导出原文传递

翻译打印收藏纠错

第一作者： Jing,Zhao

第一单位： Department of Pathology, The Affiliated Hospital of Qingdao University, Qingdao, China.

作者： Jing,Zhao ^[1] ; Uma,Krishnamurti ^[2] ; Chao,Zhang ^[3] ; Jane,Meisel ^[4] ; Zhimin,Wei ^[1] ; Aili,Suo ^[5] ; Ritu,Aneja ^[6] ; Zaibo,Li ^[7] ; Xiaoxian,Li ^[8]

作者单位： Department of Pathology, The Affiliated Hospital of Qingdao University, Qingdao, China. ^[1] Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, United States. ^[2] Biostatistics and Bioinformatics Shared Resource, Emory University, Atlanta, GA, United States. ^[3] Department of Hematology and Medical Oncology, Emory University, Atlanta, GA, United States. ^[4] Department of Oncology, The First Affiliated Hospital of Xi'an Jiaotong University, Xi'an, China. ^[5] Department of Biology, Georgia State University, Atlanta, GA, United States. ^[6] Department of Pathology, Ohio State University, Columbus, OH, United States. ^[7] Department of Pathology and Laboratory Medicine, Emory University, Atlanta, GA, United States. Electronic address: xli40@emory.edu. ^[8]

关键词 HER2 heterogeneity HER2 targeted therapy HER2+ breast cancer Immunohistochemistry staining pattern Neoadjuvant therapy Predictive Response